SCHEMBL3378784

SCHEMBL3378784

CC(C)(Oc1cccc(Oc2ccc3c(-c4ccc(Cl)cc4)noc3c2)c1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 16/20 0.47
▸ PPARG P37231 15/20 0.47
▸ PPARD Q03181 13/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ MAP4K4 O95819 2/20 0.47
▸ PDE5A O76074 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ MINK1 Q8N4C8 1/20 0.43
▸ FABP2 P12104 1/20 0.43
▸ SLC22A12 Q96S37 1/20 0.43
▸ FABP1 P07148 1/20 0.41
▸ NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13069472 0.93 PPARA (0.53) PPARAPPARGPPARDMEN1CYP1A2
SCHEMBL10662939 0.93 PPARA (0.55) PPARAPPARGPPARDMEN1CYP1A2
SCHEMBL3410208 0.90 PPARA (0.48) PPARAPPARGPPARDFABP1NR1H4
SCHEMBL3377036 0.89 PPARG (0.47) PPARAPPARGPPARDMEN1CYP2C19
SCHEMBL3376896 0.88 PPARD (0.53) PPARAPPARGPPARD
SCHEMBL3376214 0.88 PPARG (0.51) PPARAPPARGPPARDFABP1NR1H4
SCHEMBL3379784 0.88 PPARD (0.46) PPARAPPARGPPARDMEN1CYP2C19
SCHEMBL13069647 0.87 PPARG (0.46) PPARAPPARGPPARDMEN1CYP2C19
SCHEMBL13069652 0.86 PPARA (0.48) PPARAPPARGPPARDCYP2C19FABP1
SCHEMBL3375295 0.83 PPARA (0.47) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796665-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-11-17 — — EP disclosed
EP-1796665-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-11-17 — — EP disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 — — US disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 — — US disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 — — US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 — — US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 — — US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders LIPA, APOB, LCAT PPARA 111/4885PPARG 152/4885PPARD 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback